Post-transplant lymphoproliferative disorders (NORD)


00:00 / 00:00



Post-transplant lymphoproliferative disorders (NORD)

Immune system

General infections


Neonatal sepsis


Hypersensitivity reactions

Type I hypersensitivity

Food allergy



Type II hypersensitivity

Immune thrombocytopenic purpura

Autoimmune hemolytic anemia

Hemolytic disease of the newborn

Goodpasture syndrome

Rheumatic heart disease

Myasthenia gravis

Graves disease

Pemphigus vulgaris

Type III hypersensitivity

Serum sickness

Systemic lupus erythematosus

Poststreptococcal glomerulonephritis

Type IV hypersensitivity

Graft-versus-host disease

Contact dermatitis


Transplant rejection

Graft-versus-host disease

Cytomegalovirus infection after transplant (NORD)

Post-transplant lymphoproliferative disorders (NORD)


X-linked agammaglobulinemia

Selective immunoglobulin A deficiency

Common variable immunodeficiency

IgG subclass deficiency

Hyperimmunoglobulin E syndrome

Isolated primary immunoglobulin M deficiency

Thymic aplasia

DiGeorge syndrome

Severe combined immunodeficiency

Adenosine deaminase deficiency


Hyper IgM syndrome

Wiskott-Aldrich syndrome

Leukocyte adhesion deficiency

Chediak-Higashi syndrome

Chronic granulomatous disease

Complement deficiency

Hereditary angioedema


Immune system organ disorders


Ruptured spleen

Immune system pathology review

Blood transfusion reactions and transplant rejection: Pathology review

Immunodeficiencies: T-cell and B-cell disorders: Pathology review

Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review

Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review


Content Reviewers


Jake Ryan

Rishi Desai, MD, MPHSalma Ladhani, MD

Ursula Florjanczyk, MScBMC

Posttransplant lymphoproliferative disorders, or PTLDs, are uncontrolled growths of cells called lymphocytes that may occur in transplant recipients after receiving a solid organ, such as a kidney or a lung, or stem cells.

Transplant recipients require medications to suppress their immune systems which may contribute to the development of a PTLD.

Normally, immune cells can differentiate between healthy “self” and “other” cells by inspecting for the presence or absence of the normal “self” major histocompatibility complexes, also called human leukocyte antigens, present on the surface of every cell that contains a nucleus.

Healthy “self” cells are left alone.

“Others” include cells from other people or donors and “self” cells that are infected, damaged, or stressed.

Lymphocytes, are a class of rapidly dividing cells and, therefore, tends to develop mutations more often.

B-lymphocytes, or B-cells, work to develop antibodies toward invading microbes.

There’s also two types of T-lymphocytes, or T-cells.

Cytotoxic T-cells can directly destroy “other” cells and helper T-cells assist other immune cells.

Normally, if B-cells start to replicate out of control, it's the T-cells that keep them in check, and keep the immune response organized.

When people receive a transplanted organ or stem cells, they also must take immunosuppressive medications to prevent the immune system from rejecting, or attacking, the transplant.

In PTLDs, immunosuppression also prevents the destruction of abnormal lymphocytes that exhibit uncontrolled replication.

Resulting uncontrolled growth of lymphocytes can either be a benign hyperplasia, meaning there’s a large collection of noncancerous cells, or the cells can become malignant, resulting in a cancer called lymphoma.

While PTLD may result from the overproduction of T-cells, it is more typically associated with the overproduction of B-cells.


Post-transplant lymphoproliferative disorders (PTLDs) are a group of lymphoid neoplasms characterized by uncontrolled growths of lymphocytes. It occurs after someone has received a solid organ or stem cell transplant that requires immunosuppressive medications to prevent transplant rejection. PTLDs are caused by Epstein-Barr virus (EBV) infection and can originate in either type of lymphocyte: B-cells or T-cells. Diagnosis involves blood tests, a biopsy, and imaging, while treatment may include surgery, chemotherapy, and radiation.


Copyright © 2023 Elsevier, except certain content provided by third parties

Cookies are used by this site.

USMLE® is a joint program of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). COMLEX-USA® is a registered trademark of The National Board of Osteopathic Medical Examiners, Inc. NCLEX-RN® is a registered trademark of the National Council of State Boards of Nursing, Inc. Test names and other trademarks are the property of the respective trademark holders. None of the trademark holders are endorsed by nor affiliated with Osmosis or this website.